Martin Shkreli Accused of Violating Lifetime Pharma Ban
Infamous former pharmaceutical executive Martin Shkreli is being sued by the U.S. Federal Trade Commission and seven states for allegedly repeatedly violating his lifetime ban from the pharmaceutical
Former pharmaceutical executive Martin Shkreli is facing new legal action from the U.S. Federal Trade Commission (FTC) and seven states, who allege he has "flagrantly and repeatedly" violated his lifetime ban from the pharmaceutical industry, in place since 2022. Shkreli is accused of trading stock in dozens of drug companies and discussing the industry during livestreams on social media. The FTC and the states are asking a federal judge to hold Shkreli in contempt for these alleged violations.
Highlights
- Martin Shkreli is accused of violating his lifetime ban from the pharmaceutical industry, imposed in 2022.
- Allegations include Shkreli trading pharmaceutical company stocks and discussing the industry on livestreams.
- The FTC and seven states are seeking to have a federal judge find Shkreli in contempt of court.
- Proposed penalties include forcing Shkreli to divest all pharmaceutical holdings and pay fines equal to his trading profits.
- Shkreli expressed surprise at the filing, suggesting it was an attempt to limit free speech.
Details
Shkreli gained notoriety in 2015 for illegally hiking the price of a life-saving anti-parasitic drug by over 4,000 percent, leading to a seven-year prison sentence for fraud. In 2022, a federal court issued a lifetime industry ban, citing Shkreli's "egregious, deliberate, repetitive, long-running, and ultimately dangerous illegal conduct." This ban explicitly prohibits him from owning stock in pharmaceutical companies and making public statements that could influence a pharmaceutical company’s business.
According to the court filing by the FTC and the states, Shkreli's alleged violations occurred in four phases since 2022. These include stock trading competitions with other YouTubers and shorting shares of small biotech firms. He is also accused of frequently discussing pharmaceutical companies in livestreams, evaluating stocks, and predicting clinical trial outcomes. At one point, he reportedly stated, "It doesn’t matter what trades I make because I can always find a couple of biotech stocks to smoke."
Why it matters
This case is significant as it underscores the importance of upholding court orders and industry bans. If the allegations are proven true, Shkreli's actions could undermine the authority of the legal system and impact the effectiveness of similar bans in the future. The FTC emphasizes that breaches of such orders must be met with serious consequences, seeking "clear and escalating consequences" for future violations, including further financial penalties and incarceration.